Parkman R, Rappeport J, Geha R, Belli J, Cassady R, Levey R, Nathan D G, Rosen F S
N Engl J Med. 1978 Apr 27;298(17):921-7. doi: 10.1056/NEJM197804272981701.
Two patients with the Wiskott-Aldrich syndrome had complete donor lymphoid and hematopoietic engraftment after successful allogeneic bone-marrow transplantation. One patient had had only a temporary donor T-lymphocyte graft after a previous transplantation, for which he had been prepared with cytarabine and cyclophosphamide; the patient's own T lymphocytes returned six months later. A repeat transplant, for which the patient was prepared with anti-human thymocyte serum, total-body irradiation and procarbazine, resulted in complete donor engraftment. The second patient underwent a successful transplantation after similar preparation, except that procarbazine was omitted. At 11 and five months after transplantation both had normal hematopoiesis and no evidence of graft-versus-host disease. This treatment of the Wiskott-Aldrich syndrome may be a model for the correction of other genetically determined immune and hematologic bone-marrow disorders.
两名患有威斯科特-奥尔德里奇综合征的患者在成功进行异基因骨髓移植后实现了供体淋巴细胞和造血细胞的完全植入。一名患者在先前一次移植后仅出现了短暂的供体T淋巴细胞植入,那次移植前他接受了阿糖胞苷和环磷酰胺预处理;患者自身的T淋巴细胞在六个月后恢复。第二次移植时,患者接受了抗人胸腺细胞血清、全身照射和丙卡巴肼预处理,结果实现了供体的完全植入。第二名患者在经过类似预处理(除省略丙卡巴肼外)后成功进行了移植。移植后11个月和5个月时,两人的造血功能均正常,且无移植物抗宿主病的迹象。威斯科特-奥尔德里奇综合征的这种治疗方法可能成为纠正其他遗传性免疫和血液学骨髓疾病的一种模式。